ReviewBiomolecules2026
Aldehyde Detoxification in Cancer: Metabolic Guardians of the Genome.
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Reactive aldehydes are potent electrophiles that damage DNA and can ultimately promote cancer. While many aldehydes are ubiquitous in the environment, mammalian metabolism also generates high levels of endogenous aldehydes sufficient to threaten genome integrity. To protect against these aldehyde genotoxins, mammalian cells rely on diverse families of aldehyde detoxification enzymes as well as DNA repair pathways. Here, we review how aldehyde detoxification safeguards genome integrity, focusing on the aldehyde dehydrogenase (ALDH) family, alcohol dehydrogenase 5 (ADH5), and the glyoxalases. We discuss how these enzymes operate in a 2-tier model (in which tier 1 detoxification enzymes cooperate with tier 2 DNA repair pathways in a tissue-specific manner), the consequences for cancer initiation and progression when aldehyde detoxification is compromised, and the opportunities for targeting aldehydes in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.